Hipometile Edici Ajanlar
Özet
Hipometile edici ajanlar (HMA'lar) olan azasitidin ve desitabin, DNA metiltransferazları inhibe ederek tümör süpressör genlerin aktivasyonunu sağlayan sitidin analoğudur. Bu ajanlar; miyelodisplastik sendrom (MDS), kronik miyelomonositik lösemi (CMML) ve akut miyeloid lösemi (AML) gibi miyeloid malignitelerin standart tedavisinde aktif olarak kullanılmaktadır. Nükleosit taşıyıcılar aracılığıyla hücre içine alınan HMA'lar, fosforilasyon sonrası DNA veya RNA yapısına katılarak apoptozu, hücresel yaşlanmayı ve antitümöral immün yanıtı tetikler. Heterojen hasta yanıtları nedeniyle TET2, DNMT3A ve IDH1/2 gibi gen mutasyonları tedaviye yanıtı öngören biyobelirteçler olarak araştırılmaktadır. Klinik etkinliği artırmak adına HMA'lar; yoğunlaştırılmış rejimler, kök hücre nakli sonrası idame ve minimal rezidüel hastalık (MRD) takibine dayalı önleyici tedavilerde uygulanmaktadır. Ayrıca, hasta uyumunu optimize eden oral formülasyonlar (CC-486, ASTX727) ve yeni nesil dinükleotidler (guadesitabin) geliştirilmiştir. HMA'ların etkinliğini artırmak amacıyla histon deasetilaz inhibitörleri, lenalidomid ve sapasitabin ile yapılan kombinasyonlar sınırlı fayda gösterirken; venetoklaks (BCL-2 inhibitörü), IDH1/2 inhibitörleri, pevonidestat ve immün kontrol noktası inhibitörleri ile kombinasyon tedavileri miyeloid neoplazmlarda umut verici sonuçlar sunmaktadır. HMA'lar, önümüzdeki on yılda da hematolojik malignitelerin tedavisinde kritik bir bileşen olmaya devam edecektir.
Hypomethylating agents (HMAs), specifically azacitidine and decitabine, are cytidine analogs that function by inhibiting DNA methyltransferases, thereby inducing the reactivation of tumor suppressor genes. These agents are actively utilized in the standard care of myeloid malignancies, including myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). Following cellular uptake via nucleoside transporters, HMAs undergo consecutive phosphorylation and incorporate into DNA or RNA, triggering apoptosis, cellular senescence, and antitumoral immune responses. Due to heterogeneous patient responses, mutations in genes such as TET2, DNMT3A, and IDH1/2 are extensively investigated as predictive biomarkers. To optimize clinical outcomes, HMAs are being explored in intensified regimens, post-transplant maintenance, and measurable residual disease (MRD)-guided preemptive therapies. Furthermore, oral formulations (CC-486, ASTX727) and next-generation dinucleotides (guadecitabine) have been developed to enhance patient compliance and drug exposure. While combination strategies with histone deacetylase inhibitors, lenalidomide, or sapacitabine demonstrated limited efficacy, synergistic combinations with venetoclax (a BCL-2 inhibitor), selective IDH1/2 inhibitors, pevonedistat, and immune checkpoint inhibitors show promising results in overcoming resistance. Consequently, HMAs are poised to remain a cornerstone in the therapeutic arsenal against myeloid neoplasms over the next decade.
Referanslar
Diesch J, Zwick A, Garz AK, et al. A clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancers. Clinical epigenetics. Clin Epigenetics; 2016;8(1). doi:10.1186/S13148-016-0237-Y
Chabner BA, Drake JC, Johns DG. Deamination of 5-azacytidine by a human leukemia cell cytidine deaminase. Biochemical pharmacology. Biochem Pharmacol; 1973;22(21): 2763–2765. doi:10.1016/0006-2952(73)90137-8
Goodyear O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. Blood; 2010;116(11): 1908–1918. doi:10.1182/BLOOD-2009-11-249474
Duchmann M, Itzykson R. Clinical update on hypomethylating agents. International Journal of Hematology. Springer Tokyo; 2019;110(2): 161–169. doi:10.1007/S12185-019-02651-9/FIGURES/1
Schaefer M, Hagemann S, Hanna K, et al. Azacytidine inhibits RNA methylation at DNMT2 target sites in human cancer cell lines. Cancer research. Cancer Res; 2009;69(20): 8127–8132. doi:10.1158/0008-5472.CAN-09-0458
Unnikrishnan A, Vo ANQ, Pickford R, et al. AZA-MS: a novel multiparameter mass spectrometry method to determine the intracellular dynamics of azacitidine therapy in vivo. Leukemia. Leukemia; 2018;32(4): 900–910. doi:10.1038/LEU.2017.340
Decitabine: Drug information - UpToDate. [Online] https://www.uptodate.com/contents/decitabine-drug-information?search=decitabine&selectedTitle=1~38&usage_type=panel&display_rank=1&kp_tab=drug_general&source=panel_search_result
Azacitidine: Drug information - UpToDate. [Online] https://www.uptodate.com/contents/azacitidine-drug-information?search=azacitidine&source=panel_search_result&selectedTitle=1~33&usage_type=panel&kp_tab=drug_general&display_rank=1
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. The Lancet. Oncology. Lancet Oncol; 2009;10(3): 223–232. doi:10.1016/S1470-2045(09)70003-8
Jabbour E, Short NJ, Montalban-Bravo G, et al. Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN. Blood. Blood; 2017;130(13): 1514–1522. doi:10.1182/BLOOD-2017-06-788497
Thépot S, Abdelali R ben, Chevret S, et al. A randomized phase II trial of azacitidine +/- epoetin-β in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. Haematologica. Haematologica; 2016;101(8): 918–925. doi:10.3324/HAEMATOL.2015.140988
Drummond MW, Pocock C, Boissinot M, et al. A multi-centre phase 2 study of azacitidine in chronic myelomonocytic leukaemia. Leukemia. Leukemia; 2014;28(7): 1570–1572. doi:10.1038/LEU.2014.85
Braun T, Itzykson R, Renneville A, et al. Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: a phase 2 trial. Blood. Blood; 2011;118(14): 3824–3831. doi:10.1182/BLOOD-2011-05-352039
Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. Blood; 2015;126(3): 291–299. doi:10.1182/BLOOD-2015-01-621664
Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. J Clin Oncol; 2012;30(21): 2670–2677. doi:10.1200/JCO.2011.38.9429
Ali A, Penneroux J, Dal Bello R, et al. Granulomonocytic progenitors are key target cells of azacytidine in higher risk myelodysplastic syndromes and acute myeloid leukemia. Leukemia. Leukemia; 2018;32(8): 1856–1860. doi:10.1038/S41375-018-0076-2
Uy GL, Duncavage EJ, Chang GS, et al. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy. Leukemia. Leukemia; 2017;31(4): 872–881. doi:10.1038/LEU.2016.282
Unnikrishnan A, Papaemmanuil E, Beck D, et al. Integrative Genomics Identifies the Molecular Basis of Resistance to Azacitidine Therapy in Myelodysplastic Syndromes. Cell reports. Cell Rep; 2017;20(3): 572–585. doi:10.1016/J.CELREP.2017.06.067
Merlevede J, Droin N, Qin T, et al. Mutation allele burden remains unchanged in chronic myelomonocytic leukaemia responding to hypomethylating agents. Nature communications. Nat Commun; 2016;7. doi:10.1038/NCOMMS10767
Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. Leukemia; 2011;25(7): 1147–1152. doi:10.1038/LEU.2011.71
Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. Blood; 2014;124(17): 2705–2712. doi:10.1182/BLOOD-2014-06-582809
Traina F, Visconte V, Elson P, et al. Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia. Leukemia; 2014;28(1): 78–87. doi:10.1038/LEU.2013.269
Cedena MT, Rapado I, Santos-Lozano A, et al. Mutations in the DNA methylation pathway and number of driver mutations predict response to azacitidine in myelodysplastic syndromes. Oncotarget. Oncotarget; 2017;8(63): 106948–106961. doi:10.18632/ONCOTARGET.22157
Coombs CC, Sallman DA, Devlin SM, et al. Mutational correlates of response to hypomethylating agent therapy in acute myeloid leukemia. Haematologica. Haematologica; 2016;101(11): e457–e460. doi:10.3324/HAEMATOL.2016.148999
Emadi A, Faramand R, Carter-Cooper B, et al. Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia. American journal of hematology. Am J Hematol; 2015;90(5): E77–E79. doi:10.1002/AJH.23965
Shen L, Kantarjian H, Guo Y, et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. J Clin Oncol; 2010;28(4): 605–613. doi:10.1200/JCO.2009.23.4781
Fandy TE, Herman JG, Kerns P, et al. Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies. Blood. Blood; 2009;114(13): 2764–2773. doi:10.1182/BLOOD-2009-02-203547
Li S, Garrett-Bakelman FE, Chung SS, et al. Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature medicine. Nat Med; 2016;22(7): 792–799. doi:10.1038/NM.4125
Meldi K, Qin T, Buchi F, et al. Specific molecular signatures predict decitabine response in chronic myelomonocytic leukemia. The Journal of clinical investigation. J Clin Invest; 2015;125(5): 1857–1872. doi:10.1172/JCI78752
Santini V, Allione B, Zini G, et al. A phase II, multicentre trial of decitabine in higher-risk chronic myelomonocytic leukemia. Leukemia. Leukemia; 2018;32(2): 413–418. doi:10.1038/LEU.2017.186
Liu Y, Siejka-Zielińska P, Velikova G, et al. Bisulfite-free direct detection of 5-methylcytosine and 5-hydroxymethylcytosine at base resolution. Nature biotechnology. Nat Biotechnol; 2019;37(4): 424–429. doi:10.1038/S41587-019-0041-2
Tibaldi C, Giovannetti E, Tiseo M, et al. Correlation of cytidine deaminase polymorphisms and activity with clinical outcome in gemcitabine-/platinum-treated advanced non-small-cell lung cancer patients. Annals of oncology : official journal of the European Society for Medical Oncology. Ann Oncol; 2012;23(3): 670–677. doi:10.1093/ANNONC/MDR280
Welch JS, Petti AA, Miller CA, et al. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. The New England journal of medicine. N Engl J Med; 2016;375(21): 2023–2036. doi:10.1056/NEJMOA1605949
Ades L, Guerci-Bresler A, Cony-Makhoul P, et al. A phase II study of the efficacy and safety of an intensified schedule of azacytidine in intermediate-2 and high-risk patients with myelodysplastic syndromes: a study by the Groupe Francophone des Myelodysplasies (GFM). Haematologica. Ferrata Storti Foundation; 2019;104(4): e131. doi:10.3324/HAEMATOL.2018.203885
Schroeder T, Rautenberg C, Haas R, et al. Hypomethylating agents for treatment and prevention of relapse after allogeneic blood stem cell transplantation. International journal of hematology. Int J Hematol; 2018;107(2): 138–150. doi:10.1007/S12185-017-2364-4
de Lima M, Oran B, Champlin RE, et al. CC-486 Maintenance after Stem Cell Transplantation in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndromes. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant; 2018;24(10): 2017–2024. doi:10.1016/J.BBMT.2018.06.016
Huls G, Chitu DA, Havelange V, et al. Azacitidine maintenance after intensive chemotherapy improves DFS in older AML patients. Blood. Blood; 2019;133(13): 1457–1464. doi:10.1182/BLOOD-2018-10-879866
Pan J, Altman D, Wilde L. Measurable Residual Disease-Guided Treatment to Prevent Relapse in Acute Myeloid Leukemia and Myelodysplastic Syndrome. Frontiers in Oncology. Frontiers Media SA; 2020;10. doi:10.3389/FONC.2020.576924
Fraison JB, Mekinian A, Grignano E, et al. Efficacy of Azacitidine in autoimmune and inflammatory disorders associated with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leukemia research. Leuk Res; 2016;43: 13–17. doi:10.1016/J.LEUKRES.2016.02.005
Savona MR, Malcovati L, Komrokji R, et al. An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults. Blood. The American Society of Hematology; 2015;125(12): 1857. doi:10.1182/BLOOD-2014-10-607341
Issa JPJ, Roboz G, Rizzieri D, et al. Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study. The Lancet. Oncology. Lancet Oncol; 2015;16(9): 1099–1110. doi:10.1016/S1470-2045(15)00038-8
Garcia-Manero G, McCloskey JK, Griffiths EA, et al. Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study. Blood. Elsevier; 2021;138(Supplement 1): 66. doi:10.1182/BLOOD-2021-144648
Cameron EE, Bachman KE, Myöhänen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nature genetics. Nat Genet; 1999;21(1): 103–107. doi:10.1038/5047
Khan C, Pathe N, Fazal S, et al. Azacitidine in the management of patients with myelodysplastic syndromes. Therapeutic Advances in Hematology. SAGE Publications; 2012;3(6): 355. doi:10.1177/2040620712464882
Kantarjian HM, Begna KH, Altman JK, et al. Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). Cancer. Cancer; 2021;127(23): 4421–4431. doi:10.1002/CNCR.33828
Yang H, Bueso-Ramos C, Dinardo C, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. Leukemia; 2014;28(6): 1280–1288. doi:10.1038/LEU.2013.355
Zeidan AM, Knaus HA, Robinson TM, et al. A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. Clinical cancer research : an official journal of the American Association for Cancer Research. NIH Public Access; 2018;24(15): 3519. doi:10.1158/1078-0432.CCR-17-3763
Konopleva M, Pollyea DA, Potluri J, et al. Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia. Cancer discovery. Cancer Discov; 2016;6(10): 1106–1117. doi:10.1158/2159-8290.CD-16-0313
DiNardo CD, Rausch CR, Benton C, et al. Clinical experience with the BCL2-inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies. American journal of hematology. Am J Hematol; 2018;93(3): 401–407. doi:10.1002/AJH.25000
Liu X, Gong Y. Isocitrate dehydrogenase inhibitors in acute myeloid leukemia. Biomarker Research. BioMed Central; 2019;7(1). doi:10.1186/S40364-019-0173-Z
